MRUS - Merus doses first patient in phase 1/2 lung cancer study

Merus N.V. (MRUS) announces that the first patient has been treated in its phase 1/2 dose escalation and expansion trial evaluating MCLA-129 for the treatment of patients with advanced non-small cell lung cancer ((NSCLC)) and other solid tumors.The phase 1/2, open-label clinical trial of MCLA-129 consists of dose escalation followed by dose expansion.Primary objectives of phase 1 are to determine the maximum tolerated dose and/or the recommended phase 2 dose, and the objectives of phase 2 are to evaluate safety, tolerability and potential clinical activity of the recommended phase 2 dose in patients with advanced solid tumors.

For further details see:

Merus doses first patient in phase 1/2 lung cancer study